BBHC
SNDX icon

Brown Brothers Harriman & Co’s Syndax Pharmaceuticals SNDX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.8K Hold
128
– – ﹤0.01% 1679
2026
Q1 		$2.99K Hold
128
– – ﹤0.01% 1628
2025
Q4 		$2.69K Hold
128
– – ﹤0.01% 1673
2025
Q3 		$1.97K Hold
128
– – ﹤0.01% 1566
2025
Q2 		$1.2K Buy
+128
New +$1.41K ﹤0.01% 1482

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Brown Brothers Harriman & Co's SNDX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 128 shares worth $2.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Brown Brothers Harriman & Co first reported a position in SNDX in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.99K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Brown Brothers Harriman & Co held 128 shares of Syndax Pharmaceuticals worth $2.8K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1679 holding.
  • Brown Brothers Harriman & Co first reported a position in Syndax Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Brown Brothers Harriman & Co's Syndax Pharmaceuticals position peaked at $2.99K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.